866-997-4948(US-Canada Toll Free)

EpiCast Report: Hyperparathyroidism - Epidemiology Forecast to 2025

Published By :

GlobalData

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 57 Pages

EpiCast Report: Hyperparathyroidism - Epidemiology Forecast to 2025

Summary

HPT is a disorder of the parathyroid gland that is caused due to presence of excessive parathyroid hormone (PTH) in the bloodstream. An increase in the activity of parathyroid glands, due to intrinsic abnormal changes, causes alteration of the excretion of PTH, and is known as PHPT. However, an extrinsic abnormal change affecting calcium homoeostasis, which stimulates production of PTH, is known as SHPT. In THPT, a state of autonomous secretion of PTH usually occurs as a result of longstanding CKD.

To forecast the diagnosed prevalent cases of PHPT, total prevalent cases for SHPT, and diagnosed prevalent cases of THPT in the 7MM, GlobalData epidemiologists conducted a thorough literature review to find country-specific sources that provided data for the above-mentioned segmentations of the general population in the 7MM. In order to improve the accuracy of the forecast diagnosed prevalent cases of PHPT, total prevalent cases for SHPT, and diagnosed prevalent cases of THPT, GlobalData epidemiologists used studies that provided data based on uniform diagnostic criteria and disease definition for these parameters across the 7MM.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of PHPT will increase from 2,055,167 cases in 2015 to 2,373,547 cases in 2025, at an Annual Growth Rate (AGR) of 1.55%. The US will have the highest number of cases of PHPT among the 7MM throughout the forecast period, while Japan will have the lowest. In the 7MM, GlobalData epidemiologists forecast that the total prevalent cases of SHPT will increase from 75,326,251 cases in 2015 to 85,592,876 cases in 2025, at an AGR of 1.36%.

Scope

- The Hyperparathyroidism (HPT) EpiCast Report provides an overview of the risk factors and global trends of HPT in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of primary HPT (PHPT), total prevalent cases for secondary HPT (SHPT) (including diagnosed and undiagnosed), and diagnosed prevalent cases of tertiary HPT (THPT), based on country-specific studies published in peer-reviewed journals. The diagnosed prevalent cases of PHPT and total prevalent cases of SHPT are further segmented by sex and age (ages 20 years and above), and the diagnosed prevalent cases of THPT are segmented by sex. GlobalData epidemiologists also provide prevalent cases of SHPT in the total chronic kidney disease (CKD) pre-dialysis prevalent population and also in the total CKD dialysis prevalent population in the 7MM for the forecast period.
- The hyperparathyroidism epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hyperparathyroidism EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism market.
- Quantify patient populations in the global hyperparathyroidism market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hyperparathyroidism therapeutics in each of the markets covered.
- Understand comorbid population of CKD cases and hyperparathyroidism.
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Epidemiology 8
2.1 Disease Background 8
2.2 Risk Factors and Comorbidities 9
2.3 Global Trends 10
2.3.1 Prevalence 11
2.4 Forecast Methodology 12
2.4.1 Sources Used 12
2.4.2 Forecast Assumptions and Methods 16
2.4.3 Sources Not Used 25
2.5 Epidemiological Forecast of HPT (2015-2025) 26
2.5.1 Diagnosed Prevalent Cases 26
2.5.2 Total Prevalent Cases of SHPT 32
2.5.3 Diagnosed Prevalent Cases of THPT 42
2.6 Discussion 45
2.6.1 Epidemiological Forecast Insight 45
2.6.2 Limitations of the Analysis 46
2.6.3 Strengths of the Analysis 47
3 Appendix 48
3.1 Bibliography 48
3.2 About the Authors 52
3.2.1 Epidemiologists 52
3.2.2 Reviewers 53
3.2.3 Global Director of Therapy Analysis and Epidemiology 54
3.3 About GlobalData 55
3.4 About EpiCast 55
3.5 Disclaimer 56

1.1 List of Tables
Table 1: Risk Factors and Comorbidities of HPT 10
Table 2: Diagnositc Criteria for PHPT, SHPT, and THPT 13
Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PHPT 13
Table 4: 7MM, Sources Used to Forecast the Total Prevalent Cases of SHPT 14
Table 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of THPT 15
Table 6: 7MM, Sources Used to Forecast the Total Prevalent Cases of CKD 16
Table 7: 7MM, Diagnosed Prevalent Cases of PHPT, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 26
Table 8: 7MM, Age-Specific Diagnosed Prevalent Cases of PHPT, Ages 20 Years, Both Sexes, N (Row %), 2015 28
Table 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of PHPT, Ages 20 Years N (Row %), 2015 30
Table 10: 7MM Total Prevalent Cases of SHPT, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 33
Table 11: 7MM, Age-Specific Total Prevalent Cases of SHPT, Both Sexes, N (Row %), 2015 34
Table 12: 7MM, Sex-Specific Total Prevalent Cases of SHPT, Ages 20 Years, N (Row %), 2015 36
Table 13: 7MM, SHPT in Pre-Dialysis CKD Total Prevalent Population (Stages 3-5), Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 39
Table 14: 7MM, SHPT in Dialysis CKD Total Prevalent Population (Stage 5D), Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 41
Table 15: 7MM, Diagnosed Prevalent Cases of THPT, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 42
Table 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of THPT, Ages 20 Years, N (Row %), 2015 44

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of PHPT, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 27
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of PHPT, Ages 20 Years, Both Sexes, N, 2015 29
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of PHPT, Ages 20 Years, 2015 31
Figure 4: 7MM, Age-Standardized Diagnosed Prevalent Cases of PHPT, Ages 20 Years, N, 2015 32
Figure 5: 7MM, Total Prevalent Cases of SHPT, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 33
Figure 6: 7MM, Age-Specific Total Prevalence of SHPT, Ages 20 Years, Both Sexes, N, 2015 35
Figure 7: 7MM, Sex-Specific Total Prevalent Cases of SHPT, Ages 20 Years, N, 2015 37
Figure 8: 7MM, Age-Standardized Total Prevalent Cases of SHPT, Ages 20 Years, N, 2015 38
Figure 9: 7MM, SHPT in Pre-Dialysis CKD Total Prevalent Population (Stages 3-5), Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 40
Figure 10: 7MM, SHPT in Dialysis CKD Total Prevalent Population (Stages 5D), Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 41
Figure 11: 7MM, Diagnosed Prevalent Cases of THPT, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 43
Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of THPT, Ages 20 Years, N, 2015 45

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *